<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03558854</url>
  </required_header>
  <id_info>
    <org_study_id>0246/2018</org_study_id>
    <nct_id>NCT03558854</nct_id>
  </id_info>
  <brief_title>Evaluation of Effectiveness of Acetylsalicylic Acid on Markers of Vascular Dysfunction in Scleroderma Patients</brief_title>
  <official_title>Evaluation of Effectiveness of Acetylsalicylic Acid on Markers of Vascular Dysfunction in Patients With Systemic Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal University of São Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Systemic sclerosis is a chronic autoimmune disease characterized by vascular changes in the
      microcirculation (small blood vessels) and progressive fibrosis of the skin and internal
      organs. It is believed that vascular changes, expressed early by the Raynaud phenomenon,
      precede fibrosis and organic dysfunction. There is no available treatment that reverses the
      vascular damage caused by the disease to the moment, although there are several medications
      recommended for the relief of manifestations due to vascular injury. Acetylsalicylic acid
      (ASA) is one of the medications that can be used for the treatment of vascular injury present
      in systemic sclerosis, but still without a fully proven benefit. This study aims to evaluate
      the effectiveness of ASA on microcirculation alterations in patients with systemic sclerosis
      by performing three exams: periungual panoramic capillary microscopy, videocapillaroscopy and
      laser Doppler imaging. In addition, a blood sample will be collected for dosing the following
      vascular lesion markers: endothelin-1, von Willebrand factor, thromboxane, and
      platelet-derived, endothelial-derived and monocyte-derived microparticles.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 28, 2018</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum level of thromboxane B2</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Measured by ELISA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum level of platelet-derived, endothelial-derived and monocyte-derived microparticles</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Measured by flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum level of von Willebrand factor</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Measured by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum level of endothelin-1</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Measured by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digital blood flow</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Measured by laser Doppler imaging</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Systemic Sclerosis</condition>
  <arm_group>
    <arm_group_label>ASA group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pill containing 100 mg of acetylsalicylic acid, taken once daily for 04 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo oral capsule group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identical pill containing placebo, taken once daily for 04 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic acid</intervention_name>
    <description>Patients will be randomized to take one pill of either acetylsalicylic acid or placebo once daily for 4 weeks</description>
    <arm_group_label>ASA group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Patients will be randomized to take one pill of either acetylsalicylic acid or placebo once daily for 4 weeks</description>
    <arm_group_label>Placebo oral capsule group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fulfill Systemic sclerosis EULAR/American College of Rheumatology 2013 classification
             criteria;

          -  Pharmacological treatment with stable dosages for the last three months.

        Exclusion Criteria:

          -  Pregnancy;

          -  Use of anticoagulants, NSAIDs or antiplatelets drugs;

          -  Diagnose of other autoimmune rheumatic diseases, coronary diseases, cerebrovascular
             diseases and severe peripheral artery diseases;

          -  Active infection;

          -  Contraindication to acetylsalicylic acid use.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cristiane Kayser, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Federal University of Sao Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandra Maximiano</last_name>
    <phone>55-61-991776559</phone>
    <email>sandramaximianoo@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cristiane Kayser</last_name>
    <phone>55-11-991732117</phone>
    <email>cristiane.kayser@unifesp.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Systemic Sclerosis Outpatient Clinic, Hospital São Paulo</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristiane Kayser</last_name>
      <phone>55-11-55764239</phone>
      <email>cristiane.kayser@unifesp.br</email>
    </contact>
    <contact_backup>
      <last_name>Sandra Maximiano</last_name>
      <phone>55-61-991776559</phone>
      <email>sandramaximianoo@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>May 3, 2018</study_first_submitted>
  <study_first_submitted_qc>June 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2018</study_first_posted>
  <last_update_submitted>November 4, 2019</last_update_submitted>
  <last_update_submitted_qc>November 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of São Paulo</investigator_affiliation>
    <investigator_full_name>Cristiane Kayser</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Systemic sclerosis</keyword>
  <keyword>Acetylsalicylic acid</keyword>
  <keyword>Vascular dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Under discussion</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

